View Older Stories View More Recent Stories
-
Mizuho Reiterates Outperform Rating on Verastem (VSTM)
-
Verastem Oncology names new chairman, president of development
-
Verastem (VSTM) PT Raised to $14 at RBC Capital; 'Stock Is Oversold'
-
Verastem Oncology (VSTM) Misses Q3 EPS by 54c
-
Mizuho Reiterates Outperform Rating on Verastem (VSTM)
-
H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM)
-
Cantor Fitzgerald Reiterates Overweight Rating on Verastem (VSTM) on Dual-Program Growth Potential
-
Cantor Fitzgerald Assumes Verastem (VSTM) at Overweight
-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
Verastem (VSTM) PT Lowered to $14 at Mizuho
-
BTIG Reiterates Buy Rating on Verastem (VSTM)
-
Verastem partner reports 68.8% response rate for lung cancer drug in China study
-
Verastem Oncology (VSTM) Files $300M Mixed Shelf
-
Verastem gets fast track status for pancreatic cancer drug VS-7375
-
Verastem publishes phase 2 trial results in Journal of Clinical Oncology
-
BTIG on Verastem (VSTM): '2H25 Top Pick'
-
Verastem Oncology (VSTM) announces publication of results from Phase 1 FRAME study
-
Verastem Oncology (VSTM) Announces First Patient Dosed with VS-7375 in U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors
-
Cantor Fitzgerald Reiterates Overweight Rating on Verastem (VSTM)
-
Verastem Oncology (VSTM) Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375
-
Verastem Oncology (VSTM) announces positive results from phase 1/2 trial on Avutometinib plus Defactinib
-
Tempus AI (TEM) Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
-
Verastem Oncology (VSTM) Misses Q1 EPS by 79c
-
Verastem (VSTM) PT Raised to $19 at Jefferies
-
Verastem, Avmapki Fakzynja combination of avutometinib and defactinib approved by FDA
-
Mizuho on Verastem (VSTM): 'we continue to favor it as a top small cap biotech idea'
-
Verastem Oncology (VSTM) Prices $75M Share Offering at $7/sh
-
Verastem Oncology (VSTM) Announces U.S. IND Clearance of VS-7375
-
Jefferies Starts Verastem (VSTM) at Buy
-
Verastem (VSTM) PT Raised to $14 at Guggenheim
-
Verastem (VSTM) PT Raised to $10 at H.C. Wainwright
-
BTIG Reiterates Buy Rating on Verastem (VSTM)
-
Mizuho Reiterates Outperform Rating on Verastem (VSTM), Says 'Poised for a Breakout in 2025'
-
Verastem Oncology (VSTM) Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
-
BTIG Reiterates Buy Rating on Verastem (VSTM)
-
Verastem Oncology (VSTM) Appoints Matthew E. Ros as COO
-
Verastem Oncology (VSTM) Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China
-
RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
-
Verastem Oncology (VSTM) Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA
-
Verastem (VSTM) PT Raised to $20 at BTIG
-
Verastem Oncology (VSTM) Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib
-
B.Riley Reiterates Buy Rating on Verastem (VSTM)
-
Applied Therapeutics Inc. (APLT) Appoints John H. Johnson as Executive Chairman
-
H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM)
-
Verastem Oncology (VSTM) Provides a Clinical Update for RAMP 203 Trial
-
Verastem (VSTM) PT Raised to $9 at Mizuho
-
Verastem (VSTM) defended at Truist, 'see the weakness as an overreaction and continue to see commercial potential'
-
Verastem (VSTM) PT Lowered to $15 at Truist Securities
-
Verastem (VSTM) PT Lowered to $7 at H.C. Wainwright
-
Verastem Oncology (VSTM) Misses Q2 EPS by 61c
